...
首页> 外文期刊>Mayo Clinic Proceedings >Cardiac transplantation for end-stage congenital heart defects: the Mayo Clinic experience. Mayo Cardiothoracic Transplant Team (see comments)
【24h】

Cardiac transplantation for end-stage congenital heart defects: the Mayo Clinic experience. Mayo Cardiothoracic Transplant Team (see comments)

机译:终末期先天性心脏缺陷的心脏移植:Mayo诊所的经验。梅奥心胸移植队(见评论)

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: To review the outcome of cardiac transplantation undertaken in patients with congenital heart defects. MATERIAL AND METHODS: Between November 1991 and March 1998 at our institution, cardiac transplantation was performed in 16 patients with congenital heart disease (age range, 3 to 57 years; mean, 26.1). Preoperative diagnoses included univentricular heart (N = 4); complete transposition of the great arteries (N = 3); Ebstein's anomaly (N = 2); tetralogy of Fallot (N = 2); levotransposition (N = 2); dextrocardia, corrected transposition, ventricular and atrial septal defects, and pulmonary stenosis (N = 1); double-outlet right ventricle (N = 1); and hypertrophic obstructive cardiomyopathy (N = 1). All patients had undergone from one to five previous palliative operations. RESULTS: Four patients required permanent pacemaker implantation during the first month postoperatively because of bradycardia; more than 2 years later, another patient required a permanent pacemaker because of sick sinus syndrome. In addition, one patient had an automatic implantable cardioverter-defibrillator. Three patients required reconstruction of cardiovascular structures with use of prosthetic material (Teflon patches or donor tissue) at the time of cardiac transplantation. Actuarial 1-, 2-, and 5-year survival was 86.2 +/- 9.1%. During the first year after transplantation, two deaths occurred--one at 41 days of putative vascular rejection and the second at 60 days of severe cellular rejection. All other patients are alive and functionally rehabilitated; the mean follow-up period has been 26.1 months (range, 2 to 89.6). CONCLUSION: Cardiac transplantation for patients with congenital heart disease can be accomplished with a low perioperative mortality and an excellent medium-term survival despite the challenges presented by the technical difficulties during invasive diagnostic procedures and at operation and the need for adherence to long-term multiple-drug therapy in this patient population.
机译:目的:探讨先天性心脏病患者的心脏移植结果。材料与方法:1991年11月至1998年3月,在我们的机构中​​,对16例先天性心脏病(年龄3至57岁;平均26.1岁)的患者进行了心脏移植。术前诊断包括单室心脏(N = 4);完全转移大动脉(N = 3); Ebstein异常(N = 2);法洛四联症(N = 2);左转位(N = 2);右旋心,纠正的移位,心室和房间隔缺损以及肺动脉狭窄(N = 1);双出口右心室(N = 1);和肥厚性梗阻性心肌病(N = 1)。所有患者先前均接受过一到五次姑息手术。结果:四名患者因心动过缓而在术后第一个月需要永久性起搏器植入。超过2年后,另一位患者因病窦综合征而需要永久起搏器。另外,一名患者装有自动植入式心脏复律除颤器。三名患者在心脏移植时需要使用修复材料(聚四氟乙烯贴片或供体组织)重建心血管结构。 1年,2年和5年的精算生存率为86.2 +/- 9.1%。在移植后的第一年,发生了两例死亡-一次死于假定的血管排斥反应41天,第二次死于严重的细胞排斥反应60天。所有其他患者都还活着,并且功能得到了康复;平均随访期为26.1个月(范围2至89.6)。结论:尽管有创诊断过程和手术中存在技术难题,并且需要长期坚持治疗,但先天性心脏病患者的心脏移植可以降低围手术期死亡率,并具有出色的中期生存率。此患者人群的药物治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号